Pharmaceutical

Relmada acquires Tourette’s therapy rights from Asarina

Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.

Feb 9, 2025 - 06:00
Relmada acquires Tourette’s therapy rights from Asarina
Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.
Read the original article

Tags:

Previous Article

How AI is streamlining cell and gene therapy manufacturing

Next Article

Treating alcohol addiction: filling the medication gap

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Africa: Unleashing the potential of the new superpower in clinical trials

Africa: Unleashing the potential of the new superpower ...

Mar 21, 2023

FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment

FDA approves AbbVie’s VYALEV for advanced Parkinson’s t...

Oct 20, 2024

STAT+: Most clinical trials run in Canada failed to take basic steps toward transparency, analysis finds

STAT+: Most clinical trials run in Canada failed to tak...

Nov 27, 2023